Nonclinical Safety Assessment for Small Molecules and Biologic Drug Development (6of14) REdI 2018

CDER’s Hanan Ghantous discusses PINDs, INDs and NDAs/BLAs, and the FDA’s roles and responsibilities related to nonclinical safety assessment (pharmacology/toxicology) in detail. He provides case studies and a comparison of the development of biologic drugs vs. small molecule drugs will be presented.
_______________________________
FDA CDER’s Small Business and Industry Assistance (SBIA) educates and provides assistance in understanding the regulatory aspects of human drug products & clinical research.
Upcoming training and free continuing education credits: www.fda.gov/cdersbia
CDER SBIA 2018 Playlist: • 2018 CDER Small Busine...
LinkedIn: / cder-small-business-an...
Training resources: www.fda.gov/cderbsbialearn
Twitter: / fda_drug_info
CDER small business e-mail update subscription: updates.fda.gov/subscriptionm...
Email: [e-mail]
Phone: [phone] I [phone]